Innovative Antihypertensive Drugs Approved in Rapid Succession: Feizi Chemical Secures Urapidil Supply Chain with Stable Provision of Core Intermediates
In March 2024, Idorsia’s dual endothelin receptor antagonist aprocitentan (TRYVIO) received FDA approval, breaking a nearly 40-year stalemate without the launch of antihypertensive drugs with novel mechanisms. In May 2026, AstraZeneca’s baxdrostat (Baxfendy), the world’s first aldosterone synthase inhibitor, was approved. Meanwhile, the siRNA drug zilebesiran, developed by Roche and Alnylam, has entered a Phase III clinical trial involving 10,000 patients and is expected to file for marketing approval in 2028. As the innovative antihypertensive drug sector experiences a new wave of explosive growth, the stable supply of classic antihypertensive drugs remains an indispensable part of the industry chain. Shijiazhuang Feizi Chemical Technology Co., Ltd., deeply engaged in the field of antihypertensive drug intermediates, has achieved large-scale, stable supply of its core product, 1-(2-Methoxyphenyl)piperazine hydrochloride (CAS 5464-78-8), a key intermediate for urapidil hydrochloride.
The Core Node in the Urapidil Synthesis Chain
1-(2-Methoxyphenyl)piperazine hydrochloride (CAS 5464-78-8) is a crucial side-chain intermediate for synthesizing urapidil hydrochloride. As a selective α1-adrenergic receptor blocker with concurrent central 5-HT1A receptor agonist activity, urapidil holds an irreplaceable clinical position in treating hypertensive emergencies, perioperative blood pressure control, and severe hypertension. Its injectable formulation is a commonly used antihypertensive agent in emergency and anesthesia departments.
In the synthesis route of urapidil, 1-(2-Methoxyphenyl)piperazine hydrochloride (CAS 5464-78-8) provides the piperazine side-chain fragment of the molecule. It condenses with a uracil ring intermediate to construct the complete molecular skeleton of urapidil. The purity and quality of this intermediate directly affect the yield and quality of the final product, making it the core node in the urapidil synthesis chain.
Multi-Platform Coverage and Synergistic Supply of Dual Intermediates
Feizi Chemical’s 1-(2-Methoxyphenyl)piperazine hydrochloride (CAS 5464-78-8) has been listed on multiple mainstream domestic chemical e-commerce platforms, boasting extensive product coverage and high customer recognition. Relying on mature synthetic processes, the company can stably provide high-purity products, meeting the multi-tiered needs of API (Active Pharmaceutical Ingredient) manufacturers from R&D to large-scale production.
In addition to this product, Feizi Chemical simultaneously supplies another key intermediate for urapidil, 6-Amino-1,3-dimethyluracil (CAS 6642-31-5). This establishes a synergistic dual-intermediate supply capability for the urapidil synthesis chain, providing customers with the convenience of one-stop procurement.
Deepening Upstream Integration to Support the Antihypertensive Drug Industry Chain
The global population of hypertension patients has exceeded 1.4 billion, with a significant proportion suffering from inadequate blood pressure control, leading to continuous growth in demand for various antihypertensive drugs. Amid the continuous emergence of antihypertensive drugs with novel mechanisms, classic antihypertensive drugs remain the cornerstone of hypertension treatment. Through in-depth process optimization and stable supply of key intermediates, Feizi Chemical provides reliable support for the upstream segment of the antihypertensive drug industry chain.
